R. Schreiber

van Veggel, L., Schepers, M., Tiane, A., Kumar, V., Willems, E., Rombaut, B., Noordijk, J., Vangansewinkel, T., Li, A., Wolfs, E., Ozcan, B., Nouboers, E., Moya, P. R., Sauer, D. B., Diliën, H., Hellings, N., Schreiber, R., & Vanmierlo, T. (2025). EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis. Biomedicine & Pharmacotherapy, 186, 117960. Article 117960. https://doi.org/10.1016/j.biopha.2025.117960

Magaraggia, I., Krauskopf, J., Ramaekers, J. G., You, Y., de Nijs, L., Briedé, J. J., & Schreiber, R. (2025). Harnessing brain-derived extracellular vesicles to support RDoC-based drug development. Neuroscience Applied, 4, Article 105406. https://doi.org/10.1016/j.nsa.2024.105406

van Veggel, L., Voets, A. M., Vanmierlo, T., & Schreiber, R. (2024). Insights from an academic endeavor into central nervous system drug discovery. Neural Regeneration Research, 20(6), 1717-1718. https://doi.org/10.4103/NRR.NRR-D-24-00340

van Veggel, L., Mocking, T. A. M., Sijben, H. J., Liu, R., Gonzalez, M. G., Dilweg, M. A., Royakkers, J., Li, A., Kumar, V., Dong, Y. Y., Bullock, A., Sauer, D. B., Dilien, H., van Westen, G. J. P., Schreiber, R., Heitman, L. H., & Vanmierlo, T. (2024). Still in Search for an EAAT Activator: GT949 Does Not Activate EAAT2, nor EAAT3 in Impedance and Radioligand Uptake Assays. Acs Chemical Neuroscience, 15(7), 1424-1431. https://doi.org/10.1021/acschemneuro.3c00731

van Veggel, L., Schepers, M., Tiane, A., Rombaut, B., Royakkers, J., Dilien, H., Hellings, N., Moya, P., Schreiber, R., & Vanmierlo, T. (2023). EAAT3 modulation of the oligodendrocyte lineage in in vitro and in vivo models of Multiple Sclerosis. Glia, 71, E721-E721.

Huisman, G., Menke, M., Grundmann, O., Schreiber, R., & Mason, N. (2023). Examining the Psychoactive Differences between Kratom Strains. International Journal of Environmental Research and Public Health, 20(14), Article 6425. https://doi.org/10.3390/ijerph20146425

Klaas, S., Siva, J. B., Bak, M., Govers, M., & Schreiber, R. (2023). The pathophysiology of Post SSRI Sexual Dysfunction: Lessons from a case study. Biomedicine & Pharmacotherapy, 161(1), Article 114166. https://doi.org/10.1016/j.biopha.2022.114166

Zalm, P. W. V., Ahmed, S., Fatou, B., Schreiber, R., Barnaby, O., Boxer, A., Zetterberg, H., Steen, J. A., & Steen, H. (2023). Meta-analysis of published cerebrospinal fluid proteomics data identifies and validates metabolic enzyme panel as Alzheimer's disease biomarkers. Cell Reports Medicine, 4(4), Article 101005. https://doi.org/10.1016/j.xcrm.2023.101005

Kong, L., He, Q., Li, Q., Schreiber, R., Kaitin, K. I., & Shao, L. (2023). Rapid progress in neuroimaging technologies fuels central nervous system translational medicine. Drug Discovery Today, 28(3), Article 103485. https://doi.org/10.1016/j.drudis.2023.103485

Schreiber, R., Campbell, U., Quinton, M. S., Hardy, L. W., Fang, Q. K., & Lew, R. (2022). In vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo. Biomedicine & Pharmacotherapy, 153, Article 113359. https://doi.org/10.1016/j.biopha.2022.113359